摘要
目的观察分析孟鲁司特钠(商品名:顺尔宁)与吸入性糖皮质激素(布地奈德)联合用药治疗小儿哮喘的临床疗效。方法 98例小儿哮喘患儿作为研究对象,随机分为对照组和观察组,每组49例。对照组患儿在对症支持治疗基础上给予布地奈德进行雾化吸入治疗,观察组患儿在对照组基础上加用顺尔宁治疗。比较两组患儿的临床症状消失时间、住院时间及治疗后肺功能指标[第一秒用力呼气容积(FEV1)、最大呼气峰流速(PEF)、嗜酸性粒细胞计数(Eos)]、血气分析指标(动脉血氧分压、动脉血二氧化碳分压)、临床疗效。结果观察组患儿的湿啰音消失时间、哮鸣音消失时间、咳嗽消失时间和住院时间均明显短于对照组,差异具有统计学意义(P<0.05)。治疗后,观察组患儿的FEV1、PEF水平分别为(1.94±0.48)L、(3.34±0.96)L/s,均明显高于对照组的(1.53±0.35)L和(2.75±0.85)L/s,差异均有统计学意义(P<0.05);而观察组患儿的Eos(0.28±0.06)%明显低于对照组的(0.39±0.11)%,差异有统计学意义(P<0.05)。治疗后,观察组患儿的动脉血氧分压(76.3±1.2)mm Hg(1 mm Hg=0.133 kPa)明显高于对照组的(68.5±1.3)mm Hg,动脉血二氧化碳分压(32.3±1.2)mm Hg明显低于对照组的(38.5±1.3)mm Hg,差异均有统计学意义(P<0.05)。治疗后,观察组的治疗总有效率97.96%明显高于对照组的77.55%,差异具有统计学意义(P<0.05)。结论采用顺尔宁联合吸入性糖皮质激素的方式治疗小儿哮喘,能够促进临床症状的快速缓解,有效提高单纯使用糖皮质激素的临床疗效。
Objective To observe and analyzed the clinical efficacy of montelukast sodium(trade name:Shunerning)combined with inhaled glucocorticoids(budesonide)in the treatment of children with asthma.Methods A total of 98 children with asthma as study subjects were randomly divided into control group and observation group,with 49 cases in each group.The control group was treated by budesonide atomization inhalation on the basis of symptomatic support treatment,and the observation group was treated by Sunerning on the basis of the control group.The disappearance time of clinical symptoms,hospitalization time,pulmonary function parameters[forced expiratory volume in the first second(FEV1),peak expiratory flow(PEF),eosinophil(Eos)count]and blood gas parameters(arterial partial pressure of oxygen and carbon dioxide)before and after treatment and clinical efficacy were compared between the two groups.Results The disappearance time of moist rales,wheezing and cough and hospitalization time of the observation grop was obviously shorter than that of the control group,and the difference was statistically significant(P<0.05).After treatment,FEV1 and PEF of the observation group was(1.94±0.48)L and(3.34±0.96)L/s respectively,which was obviously higher than that of the control group(1.53±0.35)L and(2.75±0.85)L/s,and the difference was statistically significant(P<0.05).Eos(0.28±0.06)%of the observation group was obviously lower than that of the control group(0.39±0.11)%,and the difference was statistically significant(P<0.05).After treatment,arterial partial pressure of oxygen(76.3±1.2)mm Hg(1 mm Hg=0.133 kPa)of the observation group was obviously higher than that of the control group(68.5±1.3)mm Hg,and arterial partial pressure of carbon dioxide(32.3±1.2)mm Hg was obviously lower than that of the control group(38.5±1.3)mm Hg,and the difference was statistically significant(P<0.05).After treatment,the total effective rate of treatment 97.96%of the observation group was obviously higher than that of the control group 77.55%,an
作者
安龙
AN Long(Department of Pediatrics,Jinzhou Maternity and Infant Hospital,Jinzhou 121000,China)
出处
《中国现代药物应用》
2020年第17期115-117,共3页
Chinese Journal of Modern Drug Application
关键词
孟鲁司特钠
吸入性糖皮质激素
小儿哮喘
临床疗效
Montelukast sodium
Inhaled glucocorticoids
Children with asthma
Clinical efficacy
